Does Early Progesterone Prevent Pregnancy Hypertension?

Hypertensive disorders of pregnancy remain a leading cause of maternal and perinatal morbidity worldwide. Consequently, obstetricians continually seek preventative interventions during early gestation. Many fertility protocols utilize periconceptual progesterone to support early implantation and placentation. However, clinicians still debate whether this hormonal exposure alters maternal cardiovascular risks later in pregnancy.

Evaluating Periconceptual Progesterone in a Population Cohort

A massive population-based cohort study in Victoria, Australia, investigated this clinical question. Researchers analyzed pregnancy and dispensing registries spanning from 2009 through 2020. Specifically, the cohort included 386,475 nulliparous women who delivered during this period. The investigators compared patients who progesterone between six weeks preconception and the first trimester against unexposed individuals. Furthermore, the statistical analysis applied inverse probability-weighted regression adjustment to balance maternal confounders.

Overall, 5,657 women (1.5%) received periconceptual progesterone therapy. The primary outcomes evaluated the subsequent onset of gestational hypertension and preeclampsia.

Key Findings on Gestational Hypertension and Preeclampsia

Periconceptual progesterone exposure demonstrated a modest overall protective signal. In fact, treated patients showed a statistically significant reduction in any new-onset hypertensive disorders of pregnancy. The adjusted risk ratio was 0.81, reflecting a 1.72% absolute risk reduction. However, a deeper breakdown revealed that this benefit applied solely to gestational hypertension. The adjusted risk ratio for gestational hypertension was 0.60, representing a 1.69% absolute decrease.

In contrast, researchers observed no meaningful reduction in preeclampsia rates. The adjusted risk ratio for preeclampsia was 0.97, which did not achieve statistical significance. Similarly, a restricted sub-analysis of pregnancies conceived via assisted reproductive technology yielded concordant findings. In that subgroup, progesterone reduced gestational hypertension risk by 1.02% without affecting preeclampsia risk.

Clinical Implications for Obstetric Practice

Although the risk reduction reached statistical significance, the authors concluded that the absolute change remains unlikely to be clinically meaningful. Gestational hypertension typically carries lower maternal and fetal risks than preeclampsia. Because preeclampsia rates did not decline, clinicians should not prescribe early progesterone specifically for hypertensive disorder prevention. Therefore, routine preventative administration solely for blood pressure modulation is unwarranted.

Nevertheless, these findings offer reassuring safety evidence for fertility specialists. Many women undergoing assisted reproduction require luteal support. Thus, clinicians can confidently reassure patients that early progesterone therapy does not elevate vascular complications during pregnancy.

Frequently Asked Questions

Q1: Does periconceptual progesterone prevent preeclampsia?

Specifically, evidence from this large cohort demonstrated that early progesterone use did not reduce the incidence of preeclampsia or superimposed preeclampsia.

Q2: Why did gestational hypertension decrease while preeclampsia remained unchanged?

Gestational hypertension and preeclampsia involve distinct pathophysiological pathways. Furthermore, progesterone may influence maternal vascular tone without correcting the deeper placental dysfunction driving preeclampsia.

Q3: Should obstetricians prescribe progesterone to prevent pregnancy hypertension?

Current evidence does not support using progesterone solely to prevent hypertensive disorders. Therefore, clinicians should maintain established indications such as luteal phase support or recurrent pregnancy loss.

References

1. Atkinson JA et al. Periconceptual Progesterone Use and Hypertensive Disorders of Pregnancy: A Population-Based Cohort Study. BJOG. 2026 Nov 05. doi: 10.1111/1471-0528.70355. PMID: 42987862.
2. Melo P, Devall A, Shennan AH, et al. Vaginal micronised progesterone for the prevention of hypertensive disorders of pregnancy: a systematic review and meta-analysis. BJOG. 2024;131(6):727-739. doi:10.1111/1471-0528.17705.
3. Amaral LM, Wallace K, Owens M, et al. Progesterone supplementation attenuates hypertension and the autoantibody to the angiotensin II type I receptor in response to elevated interleukin-6 during pregnancy. Am J Hypertens. 2015;28(8):1035-1042. doi:10.1093/ajh/hpu271.